(Q39783015)

14 September 2017

title

Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients--a phase I/II study (English)

1 reference

14 September 2017

0 references

metastatic breast cancer

1 reference

Stephen E Wright

1

1 reference

14 September 2017

Kathleen A Rewers-Felkins

2

1 reference

14 September 2017

Imelda S Quinlin

3

1 reference

14 September 2017

Catherine A Phillips

4

1 reference

14 September 2017

Mary Townsend

5

1 reference

14 September 2017

Ramila Philip

6

1 reference

14 September 2017

Paul Zorsky

7

1 reference

14 September 2017

Panpit Klug

8

1 reference

14 September 2017

Lijun Dai

9

1 reference

14 September 2017

Mohammad Hussain

10

1 reference

14 September 2017

Aabu A Thomas

11

1 reference

14 September 2017

Chithraleka Sundaramurthy

12

1 reference

14 September 2017

publication date

1 January 2009

1 reference

Immunological Investigations

14 September 2017

published in

1 reference

14 September 2017

volume

38

1 reference

14 September 2017

issue

8

1 reference

14 September 2017

page(s)

820-838

1 reference

Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses.

14 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

Structure and biology of a carcinoma-associated mucin, MUC1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

Improved immunogenicity of recombinant vaccinia virus-anchored gp120 lacking gp41.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

Cancer immunology. Cancer's bulwark against immune attack: MDS cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

Remission of relapsed leukaemia during a graft-versus-host reaction. A "graft-versus-leukaemia reaction" in man?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: predictability and relation with disease advancement

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

CYTOLOGY OF BURKITT'S TUMOUR (AFRICAN LYMPHOMA)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

MUC1 cross-reactive Galα(l,3)Gal antibodies in humans switch immune responses from cellular to humoral

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08820130903278089

10.3109/08820130903278089

21 January 2018

Identifiers

DOI

1 reference

14 September 2017

1 reference